University Hospitals in Cleveland Medical Center recently discovered a new enzyme called SCoR2 that may change our treatment of obesity-related diseases.paperPublished in the journal Science Signaling, it was revealed that SCoR2 plays a key role in lipogenesis, and blocking its activity can effectively reduce weight gain, improve liver health, and lower harmful cholesterol.
Obesity and fatty liver disease are on the rise globally, making new findings even more important. Obesity is a global health crisis and is closely linked to serious diseases such as heart disease and fatty liver disease. Research shows that SCoR2 removes nitric oxide from proteins that regulate fat accumulation. When nitric oxide is removed, fat is produced. The team decided to test what happens when SCoR2 is blocked, using gene editing and developing drugs that inhibit SCoR2. Experiments in mice showed that turning off SCoR2 prevented weight gain and protected the liver from damage, while lowering bad cholesterol.
Dr. Jonathan Stamler, the first author of the paper, said: “The team looks forward to further developing this first-of-its-kind drug to prevent weight gain and lower cholesterol, which is beneficial to liver health.” The SCoR2 drug is currently under development and is scheduled to enter clinical trials in about 18 months.
This breakthrough discovery not only provides new ideas for the treatment of obesity, fatty liver disease and cardiovascular disease, but also shows that SCoR2 is a potential drug target that can treat multiple metabolic diseases at the same time. Human eating habits are already full of high-calorie foods, and the significance of this research is even more important.
(Source of first picture:Pixabay）
Further reading:
Want to buy us some coffee?
65 yuan per cup of coffee
Your coffee sponsorship will keep us going
The total amount is NT$ 0 Yuan
“Q & A about buying coffee”
New scientific and technological knowledge, updated from time to time
date:2026-02-15 01:32:00